C3.ai late Friday disclosed preliminary results for the July-ended fiscal first quarter that were far worse than expected. AI ...

C3.ai, Inc. ("C3 AI," "C3," or the "Company") (NYSE: AI), the Enterprise AI application software company, today announced ...

The CEO is resigning for health reasons. C3.ai's stock has struggled since going public in late 2020 and is down over 75%. C3 ...

Benzinga's options scanner has just identified more than 8 option transactions on C3.ai AI -1.52% Get Free Report , with a cumulative value of $239,958. Concurrently, our algorithms picked up 3 puts, ...

Figma CEO Dylan Field knows people are going to stare at his stock price. “You can’t tell people, ‘Don‘t look at the elephant ...

HII (HII), America’s largest military shipbuilder, and C3 AI (NYSE: AI), the Enterprise AI application software company, have recently announced a strategic partnership to expand digital technologies ...

A new study finds early humans ate tough grasses and tubers long before their teeth adapted, suggesting behavior, not biology, drove human evolution.

C3.ai is not profitable, and a change in CEO is on the horizon. 10 stocks we like better than C3.ai › Artificial intelligence (AI) stocks have been hot, and many experienced strong growth in 2025 ...

Upgrade your portfolio! C3.ai is a strong buy with explosive growth, top-tier partnerships, and AI exposure at a discount.

Growth boosts valuation multiples, but it doesn’t always last forever. Companies that cannot maintain it are often penalized ...

Apellis Pharmaceuticals Inc. (NASDAQ:APLS) is one of the biotech stocks to buy according to Wall Street analysts.

Founded in 2009 by Thomas Siebel, C3.ai's core purpose has always been to deliver AI solutions to enterprises. Its value ...